Castle Biosciences, Inc.
CSTLHealthcareNASDAQDiagnostics & Research
Scan Results
Daily timeframeCastle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), atopic dermatitis (AD), and uveal. The company carries a $732.8M market cap, placing it firmly in the small-cap category. The company offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test that predicts the likelihood of a positive sentinel lymph node and the risk of metastasis for patients with invasive cutaneous melanoma; TissueCypher, a risk stratification spatialomics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, and low-grade dysplasia BE; AdvanceAD-Tx, a non-invasive GEP test which is designed to guide systemic treatment selection for patients aged 12 years and older with moderateto-severe AD; DecisionDx-SCC, a GEP test for cutaneous squamous cell carcinoma; and MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions.
Market Cap
$732.8M
Beta
1.00
P/E (TTM)
—
P/E (Fwd)
-25.25
EPS (TTM)
$-0.42
EPS (Fwd)
$-0.96
ROE
-2.9%
ROA
-4.0%
Cash
$261.7M
Total Debt
$36.7M
Free CF
$12.9M
52W Change
46.1%
Annual Financials
Cash vs Debt
With $261.7M in cash and $36.7M in debt, CSTL maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow comes in at $12.9M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Return on equity stands at -2.9%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $137.0M (2022) to $344.2M (2025), reflecting a 151% increase over the period.
With cash comfortably exceeding debt, CSTL has financial flexibility that may help navigate uncertain periods. No single metric tells the full story. Reviewing CSTL's risk profile alongside its fundamentals and technical indicators provides a more complete picture.